Aeglea BioTherapeutics Garners $44,000,000 Series B Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=e6858dc9-95ca-4d03-9a43-484c567abb9f
Date 3/23/2015
Company Name Aeglea BioTherapeutics
Mailing Address 901 S. MoPac Expressway Austin, TX 78746 USA
Company Description Aeglea BioTherapeutics is a Texas based start up developing two drugs invented at UT Austin, novel engineered human enzymes that degrade the amino acids L-methionine (L-Met), or L- arginine (LArg) in the circulation. These drugs target the dependence of different tumors on L- Met or L-Arg for survival.
Proceeds Purposes The proceeds from the financing will be used to support the continued development of Aeglea’s innovative pipeline of engineered human enzymes that target diseases at the extremes of abnormal metabolism.